Actively Recruiting
Phase 3 Study to Compare the Safety and Effectiveness of Combining Dapagliflozin and Telmisartan in Adults with Type 2 Diabetes and High Blood Pressure
Led by THPharm Corp. · Updated on 2025-09-12
221
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of combination therapy using THP-00101 Dapagliflozin 10 mg and THP-00102 Telmisartan 80 mg compared to each drug alone in adults with type 2 diabetes mellitus accompanied by essential hypertension. This phase 3, randomized, double-blind, multi-center trial aims to show the superiority of the combination therapy in improving blood sugar control measured by hemoglobin A1c HbA1c and lowering mean sitting systolic blood pressure MSSBP over 12 weeks. Additional evaluations include secondary efficacy and safety of different drug combinations including THP-00103 Telmisartan 40 mg.
CONDITIONS
Brief Title
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
Research Team
T
Taehee Han, Dr.
J
Jaewoo Park
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
